Abstract
Endocrine disorders play a major role in approximately 8% to 12% of recurrent pregnancy loss (RPL). Indeed, the local hormonal milieu is crucial in both embryo attachment and early pregnancy. Endocrine abnormalities, including thyroid disorders, luteal phase defects, polycystic ovary syndrome, hyperprolactinaemia and diabetes have to be evaluated in any case of RPL. Moreover, elevated androgen levels and some endocrinological aspects of endometriosis are also factors contributing to RPL. In the present article, we review the significance of endocrine disease on RPL.
Article PDF
Similar content being viewed by others
References
Smith ML, Schust DJ, 2011 Endocrinology and recurrent early pregnancy loss. Semin Reprod Med 29: 482–490.
Jacobs PA, Hassold T 1987 Chromosome abnormalities: origin and etiology in abortions and livebirths. In: Vogel F, Sperling K, (eds) Human Genetics. Berlin: Springer-Verlag; pp, 233–244.
Practice Committee of the American Society for Reproductive Medicine, 2012 Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertil Steril 98: 1103–1111.
Mills JL, Simpson JL, Driscoll SG, et al, 1988 Incidence of spontaneous abortion among normal women and insulin-dependent women whose pregnancies were identified within 21 days of conception. N Engl J Med 319: 1617–1623.
Goddijn M, Joosten JH, Knegt AC, et al, 2004 Clinical relevance of diagnosing structural chromosome abnormalities in couples with repeated miscarriage. Hum Reprod 19: 1013–1017.
Kalinka J, Szekeres-Bartho J, 2005 The impact of dydrogesterone supplementation on hormonal profile and progesterone-induced blocking factor concentrations in women with threatened abortion. Am J Reprod Immunol 53: 166–171.
Szekeres-Bartho J, Balasch J, 2008 Progestagen therapy for recurrent miscarriage. Hum Reprod Update 14: 27–35.
Porter TF, Scott JR, 2005 Evidence-based care of recurrent miscarriage. Best Pract Res Clin Obstet Gynaecol 19: 85–101.
Arredondo F, Noble LS, 2006 Endocrinology of recurrent pregnancy loss. Semin Reprod Med 24: 33–39.
Insler V, 1992 Corpus luteum defects. Curr Opin Obstet Gynecol 4: 203–211.
Hensleigh PA, Fainstat T, 1979 Corpus luteum dysfunction: serum progesterone levels in the diagnosis and assessment of therapy for recurrent and threatened abortion. Fertil Steril 32: 396–400.
Cumming DC, Honore LH, Scott JZ, 1985 The late luteal phase in infertile women: comparison of simultaneous endometrial biopsy and progesterone levels. Fertil Steril 43: 715–719.
Arck PC, Rücke M, Rose M, et al, 2008 Early risk factors for miscarriage: a prospective cohort study in pregnant women. Reprod Biomed Online 17: 101–113.
Van der Gaast MH, Beier-Hellwig K, Fauser BC, et al, 2003 Endometrial secretion aspiration prior to embryo transfer does not reduce implantation rates. Reprod Biomed Online 7: 105–109.
Altmäe S, Esteban FJ, Stavreus-Evers A, et al, 2014 Guidelines for the design, analysis and interpretation of ‘omics’ data: focus on human endometrium., Hum Reprod Update 20: 12–28.
Karamardian LM, Grimes DA, 1992 Luteal phase deficiency effect of treatment on pregnancy rares. Am J Obstet Gynecol 167: 1391–1398.
Daya S, 1989 Efficacy of progesterone support for pregnancy in women with recurrent miscarriage: a meta-analysis of controlled trials. Br J Obstet Gynaecol 96: 275–280.
Oates-Whitehead RM, Haas DM, Carrier JA, 2003 Progestogen for preventing miscarriage. Cochrane Database Syst Rev 4: CD003511.
Fatemi HM, Popovic-Todorovic B, Papanikolaou E, et al, 2007 An update of luteal phase support in stimulated IVF cycles. Hum Reprod Update 13: 581–590.
Fauser BC, Devroey P, 2003 Reproductive biology and IVF: ovarian stimulation and luteal phase consequences. Trends Endocrinol Metab 14: 236–242.
Boomsma CM, Kavelaars A, Eijkemans MJ, et al, 2010 Ovarian stimulation for in vitro fertilization alters the intrauterine cytokine, chemokine, and growth factor milieu encountered by the embryo. Fertil Steril 94: 1764–1768.
Frasor J, Park K, Byers M, et al, 2001 Differential roles for signal transducers and activators of transcription 5a and 5b in PRL stimulation of ERalpha and ERbeta transcription. Mol Endocrinol 15: 2172–2181.
McNatty KP, Sawers RS, 1975 Relationship between the endocrine environment within the graafian follicle and the subsequent secretion of progesterone by human granulosa cells in culture. J Endocrinol 66: 391–400.
Hirahara F, Andoh N, Sawai K, Hirabuki T, Uemura T, Minaguchi H, 1998 Hypecprolacrinemic recurrent miscarriage and results of randomized bromocriptine treatment trials. Fertil Steril 70: 246–252.
Li TC, Spuijbroek MDEH, Tuckerman E, Anstie B, Loxley M, Laird SM, 2000 Endocrinological and endometrial factors in recurrent miscarriage. Br J Obstet Gynaecol 107: 1975–1980.
Glinoer D, 1998 Thyroid hyperfunction during pregnancy. Thyroid 8: 859–864.
Millar LK, Wing DA, Leung AS, Koonings PP, Montoro MN, Mestman JH, 1994 Low birth weight and preeclampsia in pregnancies complicated by hyperthyroidism. Obstet Gynecol; 84: 946–949.
Anselmo J, Cao D, Karrison T, Weiss RE, Refetoff S, 2004 Fetal loss associated with excess thyroid hormone exposure. JAMA 292: 691–695.
Allan WC, Haddow JE, Palomaki GE, et al, 2000 Maternal thyroid deficiency and pregnancy complications: implications for population screening. J Med Screen 7: 127–130.
Abalovich M, Gutierrez S, Alcaraz G, Maccallini G, Garcia A, Levalle O, 2002 Overt and subclinical hypothyroidism complicating pregnancy. Thyroid 12: 63–68.
Wakim AN, Polizotto SL, Buffo MJ, Marrero MA, Burholt DR, 1993 Thyroid hormones in human follicular fluid and thyroid hormone receptors in human granulosa cells. Fertil Steril 59: 1187–1190.
Clifford K, Rai R, Watson H, Regan L, 1994 An informative protocol for the investigation of recurrent miscarriage: preliminary experience of 500 consecutive cases. Hum Reprod 9: 1328–1332.
Baloch Z, Carayon P, Conte-Devolx, et al, 2003 Guidelines Committee, National Academy of Clinical Biochemistry. Laboratory medicine practice, guidelines. Laboratory support: for the diagnosis and monitoring of thyroid disease. Thyroid 13: 3–126.
Poppe K, Velkeniers B, Glinoer D, 2007 Thyroid disease and female reproduction. Clin Endocrinol 66: 309–321.
Marai I, Carp H, Shai S, Shabo R, Fishman G, Shoenfeld Y, 2004 Autoantibody Panel Screening in Recurrent Miscarriages. Am J Reprod Immunol 51: 235–240.
Stagnaro-Green A, Roman SH, Cobin RH, el-Harazy E, Alvarez-Marfany M, Davies TF, 1990 Detection of at-risk pregnancy by means of highly sensitive assays for thyroid autoantibodies. JAMA 264: 1422–1425.
Roberts J, Jenkins C, Wilson R, et al, 1996 Recurrent miscarriage is associated with increased numbers of CD5/20 positive lymphocytes and an increased incidence of thyroid antibodies. Eur J Endocrinol 134: 84–86.
Twig G, Shina A, Amital H, Shoenfeld Y, 2012 Pathogenesis of infertility and recurrent pregnancy loss in thyroid autoimmunity. J Autoimmun 38: J275–281.
Konova E, 2010 The role of NK cells in the autoimmune thyroid disease-associated pregnancy loss. Clin Rev Allergy Immunol 39: 176–184.
Lejeune B, Grun JP, de Nayer P, Servais G, Glinoer D, 1993 Antithyroid antibodies underlying thyroid abnormalities and miscarriage or pregnancy induced hypertension. Br J Obstet Gynaecol 100: 669–672.
Rushworth FH, Backos M, Rai R, Chilcott IT, Baxter N, Regan L, 2000 Prospective pregnancy outcome in untreated recurrent miscarriers with thyroid autoantibodies. Hum Reprod 15: 1637–1639.
Prummel MF, Wiersinga WM, 2004 Thyroid autoimmunity and miscarriage. Eur J Endocrinol 150: 751–755.
Gabbe SG, Graves CR, 2003 Management of diabetes mellitus complicating pregnancy. Obstet Gynecol 102: 857–868.
Sibai BM, 2000 Risk factors, pregnancy complications, and prevention of hypertensive disorders in women with pregravid diabetes mellitus. J Matern Fetal Med 9: 62–65.
Melamed N, Hod M, 2009 Perinatal mortality in pregestational diabetes. Int J Gynaecol Obstet 104: Suppl 1: 20–24.
Lucas M J, Leveno KJ, Williams ML, Raskin P, Whalley PJ, 1989 Early pregnancy glycosylated hemoglobin, severity of diabetes, and fetal malformations. Am J Obstet Gynecol 16: 426–431.
Kitzmiller JL, Wallerstein R, Correa A, Kwan S, 2010 Preconception care for women with diabetes and prevention of major congenital malformations. Birth Defects Res A Clin Mol Teratol 88: 791–803.
Gutaj P, Zawiejska A, Wender-Ożegowska E, Brązert J, 2013 Maternal factors predictive of first-trimester pregnancy loss in women with pregestational diabetes. Pol Arch Med Wewn 123: 21–28.
Rai R, Regan L, 2006 Recurrent miscarriage. Lancet 368: 601–611.
Nicholson W, Baptiste-Roberts K, 2011 Oral hypoglycaemic agents during pregnancy: The evidence for effectiveness and safety. Best Pract Res Clin Obstet Gynaecol 25: 51–63.
Rai R, Backos M, Rushworth F, Regan L, 2000 Polycystic ovaries and recurrent miscarriage—a reappraisal. Hum Reprod 15: 612–615.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004 Revised 2003 consensus diagnostic criteria and long-term health risks related to polycysic ovary syndrome. Fertil Steril 81: 19–25.
Christiansen OB, 2006 Evidence-based investigations and treatments of recurrent pregnancy loss. Curr Opin Obstet Gynecol 18: 304–312.
Wang JX, Davies M J, Norman RJ, 2002 Obesity increases the risk of spontaneous abortion during infertility treatment. Obes Res 10: 551–554.
Angioni S, Sanna S, Magnini R, Melis GB, Fulghesu AM, 2011 The quantitative insulin sensitivity check index is not able to detect early metabolic alterations in young patients with polycystic ovarian syndrome. Gynecol Endocrinol 27: 468–474.
Tian L, Shen H, Lu Q, Norman RJ, Wang J, 2007 Insulin resistance increases the risk of spontaneous abortion after assisted reproduction technology treatment. Clin Endocrinol Metab 92: 1430–1433.
Schachter M, Raziel A, Friedler S, Strassburger D, Bern O, Ron-El R, 2003 Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine. Hum Reprod 18: 721–727.
Sun L, Lv H, Wei W, Zhang D, Guan Y, 2010 Angiotensin-Converting enzyme D/I and plasminogen activator inhibitor-1 4G/5G gene polymorphisms are associated with increased risk of spontaneous abortions in polycystic ovarian syndrome. J Endocrinol Invest 33: 77–82.
Bastard JP, Piéroni L, Hainque B, 2000 Relationship between plasma plasminogen activator inhibitor 1 and insulin resistanceDiabetes Metab Res Rev 16: 192–201.
Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH, 2012 Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 5: CD003053.
Zolghadri J, Tavana Z, Kazerooni T, et al, 2008 Relationship between abnormal glucose tolerance test and history of previous recurrent miscarriages, and beneficial effects of metformin in these patients: a prospective clinical study. Fertil Steril 90: 727–730.
Okon MA, Laird SM, Tuckerman E, Li TC, 1998 Serum androgen levels in women who suffer recurrent miscarriage and their correlation with markers of endometrial function. Fertil Steril 69: 682–690.
Bussen S, Sutterlin M, Steck T, 1999 Endocrine abnormalities during the follicular phase in women with recurrent spontaneous abortions. Hum Reprod 14:18–20.
Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group, 2004 Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome PCOS. Hum Reprod 19: 41–47.
Cocksedge KA, Saravelos SH, Wang Q, Tuckerman E, Laird SM, Li TC, 2008 Does free androgen index predict subsequent pregnancy outcome in women with recurrent miscarriage? Hum Reprod 23: 797–802.
Massé V, Ferrari P, Boucoiran I, et al, 2011 Normal serum concentrations of anti-Mullerian hormone in a population of fertile women in their first trimester of pregnancy. Hum Reprod 26: 3431–3436.
Trout SW, Seifer DB, 2000 Do women with unexplained recurrent pregnancy loss have higher day 3 serum FSH and estradiol values? Fertil Steril 74: 335–337.
Levi AJ, Raynault MF, Bergh PA, et al, 2001 Reproductive outcome in patients with diminished ovarian reserve. Fertil Steril 76: 666–669.
Elter K, Kavak ZN, Gokaslan H, et al, 2005 Antral follicle assessment after down-regulation may be a useful tool for predicting pregnancy loss in in vitro fertilization pregnancies. Gynecol Endocrinol 21: 33–37.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pluchino, N., Drakopoulos, P., Wenger, J.M. et al. Hormonal causes of recurrent pregnancy loss (RPL). Hormones 13, 314–322 (2014). https://doi.org/10.14310/horm.2002.1505
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.14310/horm.2002.1505